Atkinson Edward Morrow III, EVP and Chief Technical Operations Officer, has demonstrated a consistent pattern of selling activity in Vertex Pharmaceuticals (VRTX) shares, with no recorded purchases across 41 transactions totaling over $23 million in sales. His recent trades, concentrated in February 2026, include eight sales ranging from $324,881 to $994,093, with the largest single transaction occurring on February 17, 2026. The filings also show derivative transactions marked as "F" (likely option exercises) alongside outright sales, such as a $789,274 transaction on February 24, 2026, followed by a $324,882 sale the next day.
Morrow’s trading history is exclusively tied to VRTX, with no activity in other equities aside from derivative dispositions (coded "D") in 89bio (ETNB) in October 2025, which carried no reported value. The absence of buy transactions and the recurring sales—including a $1.26 million disposal in February 2025—suggest a long-term divestment trend. The transactions are methodical, often clustered within days, such as the three sales totaling over $2.1 million between February 17–18, 2026. While the filings indicate stock awards (coded "A"), Morrow’s monetization of holdings through sales and derivative transactions remains the dominant theme.
AI-assisted summary